Pharvaris N.V. Director Johannes Gerardus Christiaan Petrus Schikan sold 37,600 shares in open-market transactions valued at approximately $1.33 million, according to a SEC Form 4 filing. The sales occurred over June 29 and 30, 2026, at a weighted average price of around $35.41 per share, reducing his direct holdings by 10.66% to 315,167 shares. The transaction was executed under a Rule 10b5-1 trading plan and follows a 96.5% one-year share price gain as of June 30, 2026. Since March 2026, Schikan has completed four sell trades totaling 80,000 shares as part of a broader capacity-driven reduction. Pharvaris is a late-stage biotechnology company developing deucrictibant for hereditary angioedema, with the FDA recently accepting its New Drug Application for the on-demand treatment of attacks.
Pharvaris BVDirector sold shares under a trading plan, but the sale is pre-planned and not necessarily a negative signal; the stock has gained 96.5% over the past year.